ASCENDIS HEALTH

STILL IN TALKS ON REMEDICA OFFER

ASCENDIS Health said on Friday that the report circulating in the media valuing its subsidiary Remedica at about $400 million (R5.43m) was unsubstantiated, and the Ascendis board was still involved in negotiations with regard to the Remedica offer. The group initially announced on Sens on September 25 last year relating to the strategic review of the Ascendis business, in an announcement that the company had advised its biosciences business unit had been identified as non-core to the longer-term strategy of the company and accordingly identified for divestment. The group said that it was still involved in negotiations regarding the Remedica offer, the outcome of which might have an effect on the price of the company’s shares.